Animal models provide benefits for biomedical research, but translating such findings to human physiology can be difficult. The human heart’s energy needs and functions are difficult to reproduce in other animals, such as mice and rats. One new system looks to circumvent these issues and provide a functional view of how different treatments can help ailing cells in the heart following oxygen and nutrient deprivations.
Researchers have unveiled a new silicon chip that holds human lab-grown heart muscle cells for assessing the effectiveness of new drugs. The system includes heart cells, called cardiomyocytes, patterned on the chip with electrodes that can both stimulate and measure electrical activity within the cells. The researchers discuss their work in this week’s APL Bioengineering.
These capabilities provide a way for determining how the restriction of blood supply, a dangerous state known as ischemia, changes a heart’s conduction velocity, beat frequency and important electrical intervals associated with heart function.
Today, we want to highlight an interview with billionaire investor Jim Mellon that our friend, Adam Ford of Science, Technology, and the Future, has conducted. Like us, Adam was at the Undoing Aging conference in Berlin earlier this year, and, just as we were, he was busy conducting a number of interviews with the researchers and industry thought leaders there.
Jim Mellon is an interesting figure in the industry and the cofounder of Juvenescence, a company that has been investing in a number of promising companies that are developing rejuvenation biotechnology to treat age-related diseases.
In this video, he talks about how the company formed and the investment landscape in the aging research field, and he touches upon public availability of these technologies as well as overpopulation. Jim has been closely watching the industry for some years now, and he and his company have been making a number of investments in companies that are moving towards clinical trials.
With the rise of fad diets, “superfoods,” and a growing range of dietary supplement choices, it’s sometimes hard to know what to eat.
This can be particularly relevant as we grow older and are trying to make the best choices to minimize the risk of health problems such as high blood pressure, obesity, type 2 diabetes, and heart (cardiovascular) problems.
We now have evidence these health problems also all affect brain function: they increase nerve degeneration in the brain, leading to a higher risk of Alzheimer’s disease and other brain conditions including vascular dementia and Parkinson’s disease.
Amid unrelenting chaos and violence, scientists and doctors in the Democratic Republic of Congo have been running a clinical trial of new drugs to try to combat a year-long Ebola outbreak. On Monday, the trial’s cosponsors at the World Health Organization and the National Institutes of Health announced that two of the experimental treatments appear to dramatically boost survival rates.
While an experimental vaccine previously had been shown to shield people from catching Ebola, the news marks a first for people who already have been infected. “From now on, we will no longer say that Ebola is incurable,” said Jean-Jacques Muyembe, director general of the Institut National de Recherche Biomedicale in the DRC, which has overseen the trial’s operations on the ground.
Starting last November, patients in four treatment centers in the country’s east, where the outbreak is at its worst, were randomly assigned to receive one of four investigational therapies—either an antiviral drug called remdesivir or one of three drugs that use monoclonal antibodies. Scientists concocted these big, Y-shaped proteins to recognize the specific shapes of invading bacteria and viruses and then recruit immune cells to attack those pathogens. One of these, a drug called ZMapp, is currently considered the standard of care during Ebola outbreaks. It had been tested and used during the devastating Ebola epidemic in West Africa in 2014, and the goal was to see if those other drugs could outperform it. But preliminary data from the first 681 patients (out of a planned 725) showed such strong results that the trial has now been stopped.
Three hundred and sixty-six days ago, CeCe Moore woke up to the headline that would change her world: “Suspected Golden State Killer, East Area Rapist Arrested After Eluding Authorities for Decades.” Later that day, those authorities would hold a press conference in front of the Sacramento County District Attorney’s office to explain how, a day earlier, they had finally put handcuffs on the man believed to have committed a series of sadistic rapes and murders that spread terror through California for more than 40 years. But Moore didn’t have to tune in to know how they had done it. “I knew immediately they had cracked it with genetic genealogy and GEDmatch,” she says.
She knew it because at the time, Moore was working as the genetic genealogy researcher on the PBS show Finding Your Roots and had a consulting business helping adoptees find their biological parents. To aid her searches, she regularly logged on to GEDmatch, a public database where hobbyists upload results from consumer genetic testing companies like 23andMe and Ancestry to find relatives with shared DNA and to reverse-engineer their family trees. It had come to her attention that another genealogist on the site, Barbara Rae-Venter, had been uploading files that seemed out of place, and Moore suspected they came not from family members, but from crime scenes. But she had never imagined that one of them belonged to the man believed to be one of the most notorious serial killers in US history. “This was going to be huge,” she remembers telling people that day.
But not even Moore could have predicted just how huge it would become. In the year since the dramatic arrest of Joseph James DeAngelo, the alleged Golden State Killer, investigative genetic genealogy has emerged as the most powerful new crime-fighting tool since DNA itself. The technique has been used to identify suspects in more than 50 additional cases. Its vast potential to crack tens of thousands more has given rise to a lucrative new forensic science business, the formation of dedicated family-tree-building police units, and the first-ever home DNA kit marketing campaign to get people to send in their spit to solve crimes.
Medical tourism has some overlap with the anti-aging market, but the way these consumers are thinking about their own longevity will likely bring up new questions for providers. Middle-aged Asian consumers don’t want to buy youth, they want to buy things that make them appreciate where they are right now.
Middle-aged Asian consumers are giving the anti-aging market a run for its money.
Policing power may be about to get much stronger, thanks to another advance in genetic analysis. A new technique can link the patchy, limited DNA information held in forensic databases to the rich DNA libraries held by family tree-building websites, raising further questions about genetic privacy.
Earlier this year, an ancestry database used by people looking to trace their family history was used to identify the suspected Golden State Killer, a serial killer active in California decades ago. Since his arrest in April, genealogy databases – which allow consumers to upload their DNA sequences – have been used to crack several other cold cases.
A water bottle recovered from a construction site where Tim DeSalvo – whose uncle Albert DeSalvo had confessed to being the internationally notorious Boston Strangler – gave police the DNA evidence they needed to bring closure to a case that has been a mystery for nearly 50 years, murders for which no one has ever been charged.
“This is really a story of relentlessness,’’ Boston Police Commissioner Ed Davis explained today as Massachusetts top law enforcement officials revealed that DNA preserved from the body of the Boston Strangler’s last victim—raped and murdered in 1964—can now be linked with ”99.9 percent certainty” to the late Albert DeSalvo.
”This is good evidence. This is strong evidence. This is reliable evidence,’’ Suffolk County District Attorney Dan Conley said of the new DNA result. ”But there can be no doubt.”
A widespread outbreak of Legionnaires’ disease has killed one person and sickened possibly dozens of others who were all guests at the Sheraton Atlanta Hotel. The hotel evacuated all its guests on July 15 and remains closed as of press time.
Public health officials say a dozen guests had tested positive for Legionnaires’, a bacteria that can cause a severe form of pneumonia. But according to the attorney filing a lawsuit Monday, hundreds more may have been exposed.
By the time guests were evacuated in mid-July, 49-year-old Cameo Garrett was already dead. An autopsy showed she had coronary issues and Legionnaires’ disease. Garrett went to a conference at the Sheraton a week before she died – just like Germany Greer who said he became so sick at one point he didn’t even know his own name.
A remarkable new study from scientists at Stanford University has revealed thousands of previously undiscovered small proteins produced by bacteria in the human microbiome. Almost all of these newly described proteins serve unknown functions in the human body and the researchers suggest their discovery opens up a new frontier for future therapeutic drug development.
